These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 28771603)

  • 1. Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.
    Arbour KC; Naidoo J; Steele KE; Ni A; Moreira AL; Rekhtman N; Robbins PB; Karakunnel J; Rimner A; Huang J; Riely GJ; Hellmann MD
    PLoS One; 2017; 12(8):e0182665. PubMed ID: 28771603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus.
    Marchevsky AM; Walts AE
    Hum Pathol; 2017 Feb; 60():16-23. PubMed ID: 27746267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).
    Tiseo M; Damato A; Longo L; Barbieri F; Bertolini F; Stefani A; Migaldi M; Gnetti L; Camisa R; Bordi P; Buti S; Rossi G
    Lung Cancer; 2017 Feb; 104():24-30. PubMed ID: 28212996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of PD-L1, transforming growth factor-β expression and tumor-infiltrating CD8
    Duan J; Liu X; Chen H; Sun Y; Liu Y; Bai H; Wang J
    Thorac Cancer; 2018 Nov; 9(11):1341-1353. PubMed ID: 30168897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma.
    Owen D; Chu B; Lehman AM; Annamalai L; Yearley JH; Shilo K; Otterson GA
    J Thorac Oncol; 2018 Aug; 13(8):1204-1212. PubMed ID: 29702286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor immunity is related to
    Imai H; Kaira K; Hashimoto K; Nitanda H; Taguchi R; Yanagihara A; Umesaki T; Yamaguchi O; Mouri A; Kawasaki T; Yasuda M; Kobayashi K; Sakaguchi H; Kuji I; Kagamu H
    Cancer Med; 2021 Sep; 10(18):6317-6326. PubMed ID: 34363337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffuse high intensity PD-L1 staining in thymic epithelial tumors.
    Padda SK; Riess JW; Schwartz EJ; Tian L; Kohrt HE; Neal JW; West RB; Wakelee HA
    J Thorac Oncol; 2015 Mar; 10(3):500-8. PubMed ID: 25402569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer.
    Fucikova J; Rakova J; Hensler M; Kasikova L; Belicova L; Hladikova K; Truxova I; Skapa P; Laco J; Pecen L; Praznovec I; Halaska MJ; Brtnicky T; Kodet R; Fialova A; Pineau J; Gey A; Tartour E; Ryska A; Galluzzi L; Spisek R
    Clin Cancer Res; 2019 Aug; 25(15):4820-4831. PubMed ID: 31076549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Thymic Epithelial Neoplasms.
    Higuchi R; Goto T; Hirotsu Y; Nakagomi T; Yokoyama Y; Otake S; Amemiya K; Oyama T; Omata M
    J Clin Med; 2019 Nov; 8(11):. PubMed ID: 31683962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic impact of programmed cell death 1 and its ligand and the correlation with epithelial-mesenchymal transition in thymic carcinoma.
    Funaki S; Shintani Y; Fukui E; Yamamoto Y; Kanzaki R; Ose N; Kanou T; Minami M; Mori E; Okumura M
    Cancer Med; 2019 Jan; 8(1):216-226. PubMed ID: 30600651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed death-ligand 1 expression profiling in thymic epithelial cell tumors: Clinicopathological features and quantitative digital image analyses.
    Ishihara S; Okada S; Ogi H; Kodama Y; Shimomura M; Tsunezuka H; Itoh K; Marx A; Inoue M
    Lung Cancer; 2020 Jul; 145():40-47. PubMed ID: 32402921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
    Webb JR; Milne K; Kroeger DR; Nelson BH
    Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapeutic potential of CD4 and CD8 single-positive T cells in thymic epithelial tumors.
    Yamamoto Y; Iwahori K; Funaki S; Matsumoto M; Hirata M; Yoshida T; Kanzaki R; Kanou T; Ose N; Minami M; Sato E; Kumanogoh A; Shintani Y; Okumura M; Wada H
    Sci Rep; 2020 Mar; 10(1):4064. PubMed ID: 32132638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of tumor PD-L1 expression combined with CD8
    Wang Q; Lou W; Di W; Wu X
    Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 immuno-expression assay in thymomas: Study of 84 cases and review of literature.
    Guleria P; Husain N; Shukla S; Kumar S; Parshad R; Jain D
    Ann Diagn Pathol; 2018 Jun; 34():135-141. PubMed ID: 29661720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
    Kassardjian A; Shintaku PI; Moatamed NA
    PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort.
    Cocks M; Taheri D; Ball MW; Bezerra SM; Del Carmen Rodriguez M; Ricardo BFP; Bivalacqua TJ; Sharma RB; Meeker A; Chaux A; Burnett AL; Netto GJ
    Hum Pathol; 2017 Jan; 59():55-61. PubMed ID: 27663086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes.
    Shurell E; Singh AS; Crompton JG; Jensen S; Li Y; Dry S; Nelson S; Chmielowski B; Bernthal N; Federman N; Tumeh P; Eilber FC
    Oncotarget; 2016 Sep; 7(39):64300-64308. PubMed ID: 27588404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma.
    Thapa B; Salcedo A; Lin X; Walkiewicz M; Murone C; Ameratunga M; Asadi K; Deb S; Barnett SA; Knight S; Mitchell P; Watkins DN; Boutros PC; John T
    J Thorac Oncol; 2017 May; 12(5):850-859. PubMed ID: 28257959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 expression level in different thymoma stages and thymic carcinoma: a meta-analysis.
    Chen HF; Wu LX; Li XF; Zhu YC; Pan WW; Wang WX; Xu CW; Huang JH; Wu MH; Du KQ
    Tumori; 2020 Aug; 106(4):306-311. PubMed ID: 32366210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.